Companies: Eli Lilly, J&J
ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology
ASCO ‘26 showcased significant advancements in oncology, particularly the growing role of bispecific antibodies and antibody-drug conjugates (ADCs). The conference also highlighted a potential 'RAS' revolution and a notable step change in the treatment of prostate cancer.
Executive Summary
- Bispecific antibodies and ADCs are emerging as dominant forces in oncology, targeting multiple pathways and delivering precision therapy. Both drug types have been approved for multiple malignancies and are generating registrational data across tumor types. Source
- A RAS revolution is underway, with new inhibitors showing promise in pancreatic cancer — an indication where the mutation has historically resisted therapeutic intervention. Source
- Practice-changing data in prostate cancer, including the PROTEUS trial, is reshaping standard-of-care protocols for high-risk localized and locally advanced disease. Source
- Eli Lilly and J&J are at the forefront of these developments, with both companies holding significant assets across the modalities driving this year's conversation. Source
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
ASCO '26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology
ASCO '26 showcased significant advancements in oncology, particularly the growing role of bispecific antibodies and antibody-drug conjugates (ADCs). The conference also highlighted a potential RAS revolution and a notable step change in prostate cancer treatment. For BD teams and investors, the narrative around bispecifics, ADCs, and RAS-targeted therapies signals a competitive inflection point — one that will force portfolio reassessments, trigger partnership activity, and redefine market leadership across multiple high-value indications over the next 18 months. Source
Key Takeaways
- Bispecific antibodies and ADCs are emerging as dominant forces in oncology, targeting multiple pathways and delivering precision therapy. Both drug types have been approved for multiple malignancies and are generating registrational data across tumor types. Source
- A RAS revolution is underway, with new inhibitors showing promise in pancreatic cancer — an indication where the mutation has historically resisted therapeutic intervention. Source
- Practice-changing data in prostate cancer, including the PROTEUS trial, is reshaping standard-of-care protocols for high-risk localized and locally advanced disease. Source
- Eli Lilly and J&J are at the forefront of these developments, with both companies holding significant assets across the modalities driving this year's conversation. Source
What Is Driving the Bispecifics vs. ADCs Battle?
Bispecifics can engage two targets simultaneously rather than one. Antibody-drug conjugates (ADCs) are a form of precision chemotherapy designed to deliver tumor-killing toxins directly to cancer cells while sparing healthy tissue. Both drug types have been approved for multiple malignancies. Source
ASCO '26 placed these two modalities at the center of the oncology conversation, with data spanning lung cancer, solid tumors, and hematological indications. The comparative efficacy and safety profiles of these approaches across different cancer types were a key area of discussion among clinicians and commercial teams alike.
One notable data point came from Summit and Akeso, whose PD-1/VEGF bispecific ivonescimab scored a much-needed win in the Chinese Phase III HARMONi-6 study. Ivonescimab plus chemotherapy reduced the risk of disease progression or death compared with chemotherapy alone, positioning the asset as a potential competitor in a PD-(L)1 class that has become foundational across tumor types. Source
For BD teams, the takeaway is clear: the bispecific and ADC pipelines are no longer early-stage curiosities. They are generating registrational data, securing approvals, and forcing portfolio reassessments across the industry. The question for 2027 is not whether these modalities will compete for market share — it is how quickly incumbents will need to respond with combination strategies or next-generation assets to defend their positions.
How Is the 'RAS' Revolution Changing Pancreatic Cancer?
The emergence of therapies targeting RAS mutations signals a potential paradigm shift in treating cancers driven by these mutations. RAS has long been considered one of oncology's most intractable targets, and the data presented at ASCO '26 suggests the field may be approaching a turning point. Source
Central to this narrative is the RAS(ON) inhibitor daraxonrasib, which generated significant interest based on pancreatic cancer data presented at the conference. The dataset is seen as derisking the approval pathway for such agents — a critical milestone for a target that has historically resisted therapeutic intervention and left pancreatic cancer patients with limited options. Source
Pancreatic cancer remains one of the most challenging indications in oncology, with five-year survival rates that have barely moved in decades. A clinically validated RAS inhibitor would address a substantial unmet need and could unlock significant commercial value, particularly for companies with early-mover advantage. For investors tracking the space, the daraxonrasib data represents a proof-of-concept inflection — the kind that triggers both scientific enthusiasm and competitive urgency among peers looking to enter or defend the RAS space.
What Is the Step Change in Prostate Cancer Treatment?
ASCO '26 featured practice-changing data in prostate cancer, with J&J noted for a significant shift in the treatment paradigm. The data, presented during ASCO's plenary session, points to a new approach for treating patients with high-risk localized or locally advanced prostate cancer. Source
The PROTEUS trial was among the key studies spotlighted at the conference, evaluating novel treatment approaches in this population. The results have the potential to alter standard-of-care protocols and expand the addressable market for agents that can demonstrate benefit in earlier disease settings. Source
For investors, the prostate cancer data represents a high-stakes competitive dynamic. Companies that secure label expansion into high-risk localized disease could capture meaningful market share, while those reliant on later-line positioning may face increasing pressure. The plenary presentation format — reserved for data deemed practice-changing — underscores the weight the ASCO community assigned to these results. Watch for FDA filing activity and potential label updates in the second half of 2026.
Which Companies Are Best Positioned After ASCO '26?
Eli Lilly and J&J are among the most closely watched names coming out of ASCO '26, with both companies holding significant assets across the modalities and indications driving this year's conversation. Eli Lilly's oncology pipeline continues to generate headline data, while J&J's prostate cancer franchise is being reinforced by the practice-changing results presented at the plenary session. Source
Both companies have the commercial infrastructure and R&D scale to capitalize on the trends emerging from ASCO '26. For BD teams evaluating partnership or acquisition targets, the competitive positioning of these players — and their willingness to engage in dealmaking — will be a key variable in the months ahead. Companies with RAS-targeted assets, next-generation bispecifics, or differentiated ADCs in their early-stage pipelines may find themselves in high demand as larger players look to fill gaps or accelerate timelines.
What Are the Investment Implications of ASCO '26 Data?
The advancements in bispecifics, ADCs, RAS-targeted therapies, and prostate cancer treatments present both opportunities and challenges for pharmaceutical BD teams and investors. The convergence of these modalities at ASCO '26 underscores a broader trend: oncology's therapeutic arsenal is becoming more precise, more competitive, and more capital-intensive.
Investors should monitor clinical trial progress, regulatory filings, and competitive positioning as these novel therapies move toward broader market adoption. The next 12 to 18 months will likely see a wave of label expansions, new approvals, and strategic transactions as companies seek to consolidate their positions in these high-growth segments. For BD teams, the window for securing access to RAS-targeted assets and next-generation bispecific platforms may narrow quickly as larger players move to lock in deals.
Frequently Asked Questions
What are the key therapeutic modalities highlighted at ASCO '26?
ASCO '26 emphasized bispecific antibodies and antibody-drug conjugates (ADCs) as significant advancements in cancer treatment, alongside a RAS revolution and progress in prostate cancer therapies. Both modalities have been approved for multiple malignancies and are generating registrational data across tumor types. Source
Which companies and indications are central to the ASCO '26 discussions?
Key companies include Eli Lilly and J&J, with significant focus on prostate cancer and pancreatic cancer, particularly concerning RAS mutations and novel therapeutic approaches. Both companies presented data that could reshape competitive dynamics in their respective indications. Source
What are the implications of the ASCO '26 data for pharmaceutical business development and investment?
The data suggests a shift toward targeted therapies like bispecifics and ADCs, potential breakthroughs in RAS-driven cancers, and significant competitive shifts in prostate cancer, creating opportunities and competitive pressures for BD teams and investors. Companies with early-stage RAS-targeted assets, next-generation bispecifics, or differentiated ADCs may find heightened demand from larger players looking to accelerate their oncology pipelines. Source
Related coverage
This article follows our editorial standards. Report a correction via editorial contact.
